Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma

British Journal of Cancer

Volumn 107, Issue 7, 2012, Pages 1131-1137

  Sim, S H ^a   Messenger, M P ^a   Gregory, W M ^b   Wind, T C ^a   Vasudev, N S ^a   Cartledge, J ^a   Thompson, D ^a   Selby, P J ^a   Banks, R E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

carbonic anhydrase IX; CRP; osteopontin; prognosis; RCC; renal cancer

Indexed keywords

C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHRECTOMY; NOMOGRAM; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARBONIC ANHYDRASE IV; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; OSTEOPONTIN; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866950061     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.360     Document Type: Article

References (36)

1. Altman DG, Royston P (2006) Statistics notes - The cost of dichotomising continuous variables. Br Med J 332: 1080-1080
2. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2010) Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 14: 2037-2044
3. Bellahcene A, Castronovo V, Ogbureke KUE, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226
4. Bui MHT, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9: 802-811
5. Escudier B, Albiges L (2011) Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 71: 1179-1191
6. Ficarra V, Martignoni G, Lohse C, Novara G, Pea M, Cavalleri S, Artibani W (2006) External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 175: 1235-1239
7. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168: 2395-2400
8. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247: 2543-2546
9. Hosmer DW, Lemeshow S (1999) Applied Survival Analysis: Regression Modelling of Time to Event Data. John Wiley: Chichester, West Sussex, UK, 1999, pp 138-139
10. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C (2005) Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 68: 2103-2110
11. Jagdev SPK, Gregory W, Vasudev NS, Harnden P, Sim S, Thompson D, Cartledge J, Selby PJ, Banks RE (2010) Improving the accuracy of preoperative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 103: 1649-1656
12. Karakiewicz PI, Briganti A, Chun FKH, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PFA, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ (2007a) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25: 1316-1322
13. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007b) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality-a European study of 313 patients. Cancer 110: 1241-1247
14. Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, de la Taille A, Tostain J, Mulders PFA, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valeri A, Descotes JL, Rambeaud JJ, Mejean A, Montorsi F, Bertini R, Patard JJ (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55: 287-295
15. Kim HL, Seligson D, Liu XL, Janzen N, Bui MHT, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10: 5464-5471
16. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97: 1663-1671
17. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED (2007) Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25: 4757-4764
18. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180: 510-513
19. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K (2006) Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 94: 325-331
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391
21. Papworth K, Sandlund J, Grankvist K, Ljungberg B, Rasmuson T (2010) Soluble carbonic anhydrase IX Is not an independent prognostic factor in human renal cell carcinoma. Anticancer Res 30: 2953-2957
22. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED (2009) Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 115: 2092-2103
23. Patard J-J, Fergelot P, Karakiewicz PI, Klatte T, Trinh Q-D, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123: 395-400
24. Peña C, Lathia C, Shan M, Escudier B, Bukowski RM (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16: 4853-4863
25. Ramankulov A, Lein M, Kristiansen G, Meyer H-A, Loening SA, Jung K (2007) Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 133: 643-652
26. Royston P, Altman DG (1994) Regression using fractional polynomials of continuous covariates-parsimonious parametric modeling. Appl Stat J Roy St C 43: 429-467
27. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T (2007) Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100: 556-560
28. Scatena M, Liaw L, Giachelli CM (2007) Osteopontin-a multifunctional molecule regulating chronic inflammation and vascular disease Arterioscler Thromb Vasc Biol 27: 2302-2309
29. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173: 48-51
30. Stillebroer AB, Mulders PFA, Boerman OC, Oyen WJG, Oosterwijk E (2010) Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 58: 75-83
31. UICC/AJCC TNM Classification of malignant tumours. 6th edn (2002) Ed: LH Sobin, C Wittekind. Wiley Blackwell: Chichester, West Sussex, UK
32. Vasudev NS, Brown JE, Brown SR, Rafiq R, Morgan R, Patel PM, O'Donnell D, Harnden P, Rogers M, Cocks K, Anderson K, Paul A, Eardley I, Selby PJ, Banks RE (2008) Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res 14: 1775-1781
33. Wind TC, Messenger MP, Thompson D, Selby PJ, Banks RE (2011) Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions. Ann Clin Biochem 48: 112-120
34. Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J (2000) Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 82: 1808-1813
35. Zhou GX, Ireland J, Rayman P, Finke J, Zhou M (2010) Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked Immunosorbent assay: prognostic and diagnostic potentials. Urology 75: 257-261
36. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566